Free Trial
NASDAQ:ELTX

Elicio Therapeutics Q2 2024 Earnings Report

Elicio Therapeutics EPS Results

Actual EPS
-$0.64
Consensus EPS
-$0.96
Beat/Miss
Beat by +$0.32
One Year Ago EPS
N/A

Elicio Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Elicio Therapeutics Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Monday, August 12, 2024
Conference Call Time
6:00PM ET

Earnings Documents

Elicio Therapeutics Earnings Headlines

Elicio Therapeutics reports FY24 EPS ($4.25) vs ($6.96) last year
Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
See More Elicio Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elicio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elicio Therapeutics and other key companies, straight to your email.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

View Elicio Therapeutics Profile

More Earnings Resources from MarketBeat